Tel Aviv, Israel – February 13, 2019 – MaxQ AI, a medical diagnostic AI company, today announced that through its collaboration with Intel, it was able to triple the computational performance of its ACCIPIO intracranial hemorrhage (ICH) and stroke detection platform, enabling clinicians to prioritize critical patients and provide faster, near real-time ICH diagnosis. MaxQ AI’s ACCIPIO platform uses vision algorithms comprised of machine learning neural networks capable of reading all major CT OEMs’ non-contrast CT with a goal of providing speed and confidence in diagnosing suspected ICH. Accipio Ix™ has received both FDA clearance and CE Mark certification and is being deployed through major OEM CT and PACS partners to the global acute healthcare space.
Medical errors are the third-greatest cause of death in the U.S.1 As an example, stroke patients are misdiagnosed in emergency rooms between 9 percent and 30 percent of the time2. It is projected that there will be 3.4 million stroke victims by 2030, which will cause loss or extreme hardships for patients and their families while generating $240 billion in total direct and indirect costs3.
MaxQ AI is committed to harnessing the power of AI to raise the level of acute care in hospitals with expert results that can potentially save lives, improve quality and lower healthcare costs. Based on deep-learning technologies, the Accipio lx software platform is trained to automatically analyze CT images for ICH. The acute imaging AI engine leverages deep vision and cognitive analytics to compare billions of data points to identify even rare, long-tail anomalies. The platform is capable of combining the full richness of medical imaging along with other relevant patient data.
MaxQ AI‘s Accipio Ix reduces the time needed to detect hemorrhages, enabling physicians to prioritize patient care when time is of the utmost importance. MaxQ AI’s Accipio Ix can now achieve over 300 percent acceleration in the computational flow of algorithms on Intel® AI, without impacting detection accuracy.
“Many of our world-class algorithms are written using the Intel Distribution of OpenVINO™ Toolkit and optimized for Intel® Processors, which accelerates the computational flow of the MaxQ AI Platform and enables clinicians to prioritize critical patients,” said Robert Mehler, Co-Founder and Chief Operating Officer of MaxQ AI.
The MaxQ AI ACCIPIO platform is powered by Intel® AI technologies including Intel® Xeon® and Intel® Core™ CPUs and Intel® Movidius™ VPUs, and is optimized with the Intel Distribution of OpenVINO™ toolkit and Intel® performance libraries. MaxQ AI’s ACCIPIO platform is designed to be highly sensitive to the presence of acute ICH – commonly known as a brain bleed – identifying and prioritizing patients with ICH for the treating physician. The rapid processing time enables doctors to make faster, near-real-time decisions when diagnosing stroke, traumatic brain injury and ICH, where every minute counts.
About MaxQ AI, Ltd.
MaxQ AI is at the forefront of Medical Diagnostic AI. We are transforming healthcare by empowering physicians to provide ‘smarter care’ with artificial intelligence (AI) clinical insights. Based in Tel Aviv, Israel and Andover, MA, our team of deep learning and machine vision experts develop innovative software that uses AI to interpret medical images and surrounding patient data. Working with world-class clinical and industry partners, our software enables physicians to make faster, more accurate decisions when diagnosing stroke, brain trauma and other serious conditions. To learn more, visit www.maxq.ai or follow us on Twitter and LinkedIn.
For MaxQ AI: